{"id":{"repo_id":"buffalo","oai_identifier":"oai:ubir.buffalo.edu:10477/78666"},"canonical_url":"https://search.dev.ndltd.org/etd/buffalo/oai:ubir.buffalo.edu:10477/78666","repository":{"repo_id":"buffalo","name":"Buffalo","base_url":"https://ubir.buffalo.edu/oai/request"},"display":{"title":"The Inhibitor of Apoptosis (IAP) Proteins Contribute to Acquired Chemotherapy Resistance in B-cell Neoplasms","abstract":"Ph.D.","abstract_html":"Ph.D.","abstract_has_math":false,"creators":["Runckel, Kyle"],"institution":"State University of New York at Buffalo","degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":["Hernandez-Ilizaliturri, Francisco","Roswell Park"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2018,"date_issued":"2018-10-26T02:57:51Z","date_published":"2018-10-26T02:57:51Z","updated_at":"2026-07-27T19:05:14Z","subjects":["immunology","molecular biology","microbiology"],"languages":["eng"],"rights":["Users of works found in University at Buffalo Institutional Repository (UBIR) are responsible for identifying and contacting the copyright owner for permission to reuse. University at Buffalo Libraries do not manage rights for copyright-protected works and cannot assist with permissions.","Copyright retained by author."],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/10477/78666","outbound_label":"Handle","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Hernandez-Ilizaliturri, Francisco","Roswell Park"]},{"key":"dc:creator","label":"Author","values":["Runckel, Kyle"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2018-10-26T02:57:51Z","2018","2018-08-20 16:52:26"]},{"key":"dc:publisher","label":"Institution","values":["State University of New York at Buffalo"]},{"key":"dc:type","label":"Dc Type","values":["Dissertation","Text"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["immunology","molecular biology","microbiology"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["eng"]},{"key":"dc:rights","label":"Dc Rights","values":["Users of works found in University at Buffalo Institutional Repository (UBIR) are responsible for identifying and contacting the copyright owner for permission to reuse. University at Buffalo Libraries do not manage rights for copyright-protected works and cannot assist with permissions.","Copyright retained by author."]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["http://hdl.handle.net/10477/78666"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Ph.D.","The addition of rituximab to the therapeutic regimens used to treat B-cell non-hodgkin lymphoma (B-NHL) has improved patient response rates, but it has also alter the biology of the disease in the relapse/refractory setting. The patients that relapse after receiving induction therapy containing rituximab respond less well to salvage chemotherapy regimens, and have a decreased overall survival rate. To study the molecular mechanisms controlling rituximab resistance in B-cell malignancies our group developed rituximab resistant cell lines (RRCL). These RRCLs are resistant to rituximab, as well as to chemotherapy agents. This resistance to chemotherapy agents closely mirrors what is observed clinically when lymphoma patients develop rituximab resistant disease."]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dc:title","label":"Title","values":["The Inhibitor of Apoptosis (IAP) Proteins Contribute to Acquired Chemotherapy Resistance in B-cell Neoplasms"]}]}],"canonical_facts":{"dc:contributor":["Hernandez-Ilizaliturri, Francisco","Roswell Park"],"dc:creator":["Runckel, Kyle"],"dc:date":["2018-10-26T02:57:51Z","2018","2018-08-20 16:52:26"],"dc:description":["Ph.D.","The addition of rituximab to the therapeutic regimens used to treat B-cell non-hodgkin lymphoma (B-NHL) has improved patient response rates, but it has also alter the biology of the disease in the relapse/refractory setting. The patients that relapse after receiving induction therapy containing rituximab respond less well to salvage chemotherapy regimens, and have a decreased overall survival rate. To study the molecular mechanisms controlling rituximab resistance in B-cell malignancies our group developed rituximab resistant cell lines (RRCL). These RRCLs are resistant to rituximab, as well as to chemotherapy agents. This resistance to chemotherapy agents closely mirrors what is observed clinically when lymphoma patients develop rituximab resistant disease."],"dc:format":["application/pdf"],"dc:identifier":["http://hdl.handle.net/10477/78666"],"dc:language":["eng"],"dc:publisher":["State University of New York at Buffalo"],"dc:rights":["Users of works found in University at Buffalo Institutional Repository (UBIR) are responsible for identifying and contacting the copyright owner for permission to reuse. University at Buffalo Libraries do not manage rights for copyright-protected works and cannot assist with permissions.","Copyright retained by author."],"dc:subject":["immunology","molecular biology","microbiology"],"dc:title":["The Inhibitor of Apoptosis (IAP) Proteins Contribute to Acquired Chemotherapy Resistance in B-cell Neoplasms"],"dc:type":["Dissertation","Text"]},"updated_at":"2026-07-27T19:05:14Z"}